Sunday, March 31, 2013
5Lap Walk at LDS
Friday, March 29, 2013
Today 1C Begins On Our 4th Anniversary
Monday, March 25, 2013
Blood Results
Today Erika's bloodwork shows that her neutrophils have gone lower. Doctors are concerned, therefore they are putting her on a medication that will act as her immune system. She will need to go in Thursday for more bloodwork. Most likely 1C will be postponed until her levels are higher. Her platelets are at a borderline low before she will need a transfusion. She may need one Thursday if they don't get any better. Erika's current condition is that she feels tired and weak. She tries to take walks to prevent further atrophy.
Thursday, March 21, 2013
The End of 1B Today
Today's visit is to plan for part 1C of consolidation, which begins next week, along with an assesment on her current condition after part 1B. She will be hospitalized next week. After part 1C, the CNS (central nervous system) phase will begin and will consist of two spinal taps a week and radiation therapy to the brain.
Result:
Erika's blood count is low, but not low enough for any transfusion yet. Therfore, she will need to go back in on Monday for a follow-up. Her counts need to be higher inorder to begin 1C.
Monday, March 18, 2013
Friday, March 15, 2013
Why Continuation Is Necessary
"If you are in remission why do you need to continue with chemotherapy?"
If stopping chemo immediately after remission the body has a much higher chance of relaspe. Remember when you had the flu and the doctor said to continue taking the antibiotic, even if you feel better sooner than the planned prescribed time? It is to prevent the sickness from coming back. Not only that, but if it did come back, that same medication will have a difficult time treating it. With luekemia, relapse is not good. There are only a hand full of known chemo medication that affectively treats ALL and Erika is taking them all. This is why her treatment is roughly a two year span.
Regarding the treatment she is in (the clinical trial), two years ago there was another trial done. Two groups were tested. Both were in the age range of 20-28 years old. One group did the standard treatment and the other did the pediatric treatment (which Erika is in). The group in the pediatric treatment had a significantly higher survival rate. This treatment has been on an ongoing study for the past 20 years. To date, it is the best for treating ALL in young adults.
After today's hospital visit, Dr. Ford said everything looks great and she will be admitted to LDS on the 28th of this month to begin Concolidation 1C once finishes up 1B next week.